Dublin, April 07, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering.
An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations.
The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.
There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.
Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2015. The largest expansion is expected between the years 2020 and 2025.
Profiles of 248 companies, out of over 500 involved in this area, are included in the last chapter along with their 180 collaborations.The report is supplemented with 43 Tables, 28 figures and 820 references to the literature.
Key Topics Covered:
Part I: Applications & Markets
Executive Summary
1. Introduction
2. Nanotechnologies
3. Nanotechnologies for Basic Research Relevant to Medicine
4. Nanomolecular Diagnostics
5. Nanopharmaceuticals
6. Role of Nanotechnology in Biological Therapies
7. Nanodevices & Techniques for Clinical Applications
8. Nanooncology
9. Nanoneurology
10. Nanocardiology
11. Nanopulmonology
12. Nanoorthopedics
13. Nanoophthalmology
14. Nanomicrobiology
15. Miscellaneous Healthcare Applications of Nanobiotechnology
16. Nanobiotechnology and Personalized Medicine
17. Nanotoxicology
18. Ethical and Regulatory Aspects of Nanomedicine
19. Research and Future of Nanomedicine
20. Nanobiotechnology Markets
21. References
Part II: Companies
22. Nanobiotech Companies
For more information visit http://www.researchandmarkets.com/research/r6crjq/nanobiotechnology
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Nanotechnology


Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Italy Fines Apple €98.6 Million Over App Store Dominance
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 



